Advances in understanding COPD

F1000Research

Volumn 5, Issue , 2016, Pages

  Anderson, Gary P ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

ACOS; Bronchodilators; Catabasis; Chronic Obstructive Pulmonary Disease; COPD; COPD Asthma Overlap Syndrome; Myodebilitation

Indexed keywords

EID: 85030095359     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.7018.1     Document Type: Review

References (91)

1. Tan WC Sin DD Bourbeau J: Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study. Thorax. 2015;70(9):822-9. 26048404 10.1136/thoraxjnl-2015-206938
2. Pascoe S Locantore N Dransfield MT: Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435-42. 25878028 10.1016/S2213-2600(15)00106-X
3. Nesterko AO Sapronenkov PM Arsen'ev FV: Dlitel'noe prebyvanie inorodnykh tel v trakheobronkhial'nom dereve. Klin Med (Mosk). 1989;67:112-7.
4. Rossi A Zanardi E Poletti V: Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life. Int J Chron Obstruct Pulmon Dis. 2015;10:1383-92. 26229457 10.2147/COPD.S55488 4516211
5. Bateman ED Chapman KR Singh D: Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16:92. 26233481 10.1186/s12931-015-0250-2 4531806
6. Beeh K Westerman J Kirsten A: The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53-9. 25956072 10.1016/j.pupt.2015.04.002
7. Wessler I Kirkpatrick CJ Racké K: Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. Pharmacol Ther. 1998;77(1):59-79. 9500159 10.1016/S0163-7258(97)00085-5
8. Kistemaker LE Slebos DJ Meurs H: Anti-inflammatory effects of targeted lung denervation in patients with COPD. Eur Respir J. 2015;46(5):1489-92. 26341988 10.1183/13993003.00413-2015
9. Langer D Ciavaglia CE Neder JA: Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment. Expert Rev Respir Med. 2014;8(6):731-49. 25159007 10.1586/17476348.2014.949676
10. Cho MH Castaldi PJ Hersh CP: A Genome-Wide Association Study of Emphysema and Airway Quantitative Imaging Phenotypes. Am J Respir Crit Care Med. 2015;192(5):559-69. 26030696 10.1164/rccm.201501-0148OC 4595690
11. Cabanski M Fields B Boue S: Transcriptional profiling and targeted proteomics reveals common molecular changes associated with cigarette smoke-induced lung emphysema development in five susceptible mouse strains. Inflamm Res. 2015;64(7):471-86. 25962837 10.1007/s00011-015-0820-2 4464601
12. Rangasamy T Cho CY Thimmulappa RK: Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest. 2004;114(9):1248-59. 15520857 10.1172/JCI21146 524225
13. Yao H Arunachalam G Hwang JW: Extracellular superoxide dismutase protects against pulmonary emphysema by attenuating oxidative fragmentation of ECM. Proc Natl Acad Sci USA. 2010;107(35):15571-6. 20713693 10.1073/pnas.1007625107 2932580
14. Blumental-Perry A: Unfolded protein response in chronic obstructive pulmonary disease: smoking, aging and disease: a SAD trifecta. Curr Mol Med. 2012;12(7):883-98. 22697343 10.2174/156652412801318764
15. Snider GL Hayes JA Franzblau C: Relationship between elastolytic activity and experimental emphysema-induced properties of papain preparations. Am Rev Respir Dis. 1974;110(3):254-62. 4415535 10.1164/arrd.1974.110.3.254
16. Tran I Ji C Ni I: Role of Cigarette Smoke-Induced Aggresome Formation in Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis. Am J Respir Cell Mol Biol. 2015;53(2):159-73. 25490051 10.1165/rcmb.2014-0107OC
17. Paschalaki KE Starke RD Hu Y: Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased DNA damage and senescence. Stem Cells. 2013;31(12):2813-26. 23897750 10.1002/stem.1488 4377082
18. Kasahara Y Tuder RM Taraseviciene-Stewart L: Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106(11):1311-9. 11104784 10.1172/JCI10259 387249
19. Baudiß K Ayata CK Lazar Z: Ceramide-1-phosphate inhibits cigarette smoke-induced airway inflammation. Eur Respir J. 2015;45(6):1669-80. 25614161 10.1183/09031936.00080014
20. Duan M Li WC Vlahos R: Distinct macrophage subpopulations characterize acute infection and chronic inflammatory lung disease. J Immunol. 2012;189(2):946-55. 22689883 10.4049/jimmunol.1200660
21. Anthony D McQualter JL Bishara M: SAA drives proinflammatory heterotypic macrophage differentiation in the lung via CSF-1R-dependent signaling. FASEB J. 2014;28(9):3867-77. 24846388 10.1096/fj.14-250332
22. Rutten EP Gopal P Wouters EF: Various Mechanistic Pathways Representing the Aging Process Are Altered in COPD. Chest. 2016;149(1):53-61. 26066545 10.1378/chest.15-0645
23. Seys LJ Verhamme FM Schinwald A: Role of B Cell-Activating Factor in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;192(6):706-18. 26266827 10.1164/rccm.201501-0103OC
24. Bozinovski S Seow HJ Chan SP: Innate cellular sources of interleukin-17A regulate macrophage accumulation in cigarette- smoke-induced lung inflammation in mice. Clin Sci. 2015;129(9):785-96. 26201093 10.1042/CS20140703 4613531
25. Anderson GP Bozinovski S: Acquired somatic mutations in the molecular pathogenesis of COPD. Trends Pharmacol Sci. 2003;24(2):71-6. 12559770 10.1016/S0165-6147(02)00052-4
26. Cheng L Liu J Li B: Cigarette Smoke-Induced Hypermethylation of the GCLC Gene Is Associated With COPD. Chest. 2015.149(2):474-82. 26087411 10.1378/chest.14-2309
27. Warburton D Shi W Xu B: TGF-β-Smad3 signaling in emphysema and pulmonary fibrosis: an epigenetic aberration of normal development? Am J Physiol Lung Cell Mol Physiol. 2013;304(2):L83-5. 23161884 10.1152/ajplung.00258.2012 4073936
28. Kirkham PA Caramori G Casolari P: Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(7):796-802. 21965015 10.1164/rccm.201010-1605OC 3398415
29. Stämpfli MR Anderson GP: How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol. 2009;9(5):377-84. 19330016 10.1038/nri2530
30. Hogg JC McDonough JE Suzuki M: Small airway obstruction in COPD: new insights based on micro-CT imaging and MRI imaging. Chest. 2013;143(5):1436-43. 23648907 10.1378/chest.12-1766 3653349
31. Sohal SS Soltani A Reid D: A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial-mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study. Int J Chron Obstruct Pulmon Dis. 2014;9:533-42. 24920891 10.2147/COPD.S63911 4043431
32. Knight DA Ernst M Anderson GP: The role of gp130/IL-6 cytokines in the development of pulmonary fibrosis: critical determinants of disease susceptibility and progression? Pharmacol Ther. 2003;99(3):327-38. 12951164 10.1016/S0163-7258(03)00095-0
33. Ruwanpura SM McLeod L Miller A: Deregulated Stat3 signaling dissociates pulmonary inflammation from emphysema in gp130 mutant mice. Am J Physiol Lung Cell Mol Physiol. 2012;302(7):L627-39. 22268122 10.1152/ajplung.00285.2011
34. Seo BR Bhardwaj P Choi S: Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis. Sci Transl Med. 2015;7(301):301ra130. 26290412 10.1126/scitranslmed.3010467 4837896
35. Lynch TJ Engelhardt JF: Progenitor cells in proximal airway epithelial development and regeneration. J Cell Biochem. 2014;115(10):1637-45. 24818588 10.1002/jcb.24834 4428157
36. McQualter JL Yuen K Williams B: Evidence of an epithelial stem/progenitor cell hierarchy in the adult mouse lung. Proc Natl Acad Sci U S A. 2010;107(4):1414-9. 20080639 10.1073/pnas.0909207107 2824384
37. Lai H Rogers DF: New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways. J Aerosol Med Pulm Drug Deliv. 2010;23(4):219-31. 20695774 10.1089/jamp.2009.0802
38. Dijkstra AE Boezen HM van den Berge M: Dissecting the genetics of chronic mucus hypersecretion in smokers with and without COPD. Eur Respir J. 2015;45(1):60-75. 25234806 10.1183/09031936.00093314 4498483
39. Fabbri LM Boyd C Boschetto P: How to integrate multiple comorbidities in guideline development: article 10 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc. 2012;9(5):274-81. 23256171 10.1513/pats.201208-063ST
40. Agustí A Edwards LD Rennard SI: Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483. 22624038 10.1371/journal.pone.0037483 3356313
41. Kannel WB D'Agostino RB Belanger AJ: Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J. 1987;113(4):1006-10. 3565227
42. Pharmaceuticals G: GSK and Theravance Announce Results From the SUMMIT COPD CV Survival Study. 2015. Reference Source
43. Anderson GP: Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372(9643):1107-19. 18805339 10.1016/S0140-6736(08)61452-X
44. Wenzel S Ford L Pearlman D: Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455-66. 23688323 10.1056/NEJMoa1304048 F1000 Recommendation
45. Holgate S Agusti A Strieter RM: Drug development for airway diseases: looking forward. Nat Rev Drug Discov. 2015;14(6):367-8. 26000726 10.1038/nrd4645
46. Fletcher C Peto R: The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645-8. 871704 10.1136/bmj.1.6077.1645 1607732
47. Rennard SI Vestbo J: Natural histories of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(9):878-83. 19056710 10.1513/pats.200804-035QC 2720106
48. Lange P Celli B Agustí A: Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med. 2015;373(2):111-22. 26154786 10.1056/NEJMoa1411532
49. Jensen AB Moseley PL Oprea TI: Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients. Nat Commun. 2014;5:4022. 24959948 10.1038/ncomms5022 4090719
50. Jones RC Price D Ryan D: Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med. 2014;2(4):267-76. 24717623 10.1016/S2213-2600(14)70008-6
51. Losada PM Tümmler B Wiehlmann L: Whole metagenome shotgun sequencing analysis of microbiome of cystic fibrosis-and COPD patients. Eur Respir J. 2014;44:P1212. Reference Source
52. Garcia-Nuñez M Perez-Brocal V Pomares X: Bacterial and viral microbiomes in COPD exacerbations of unidentified cause. Eur Respir J. 2014;44:P2534. Reference Source
53. Chin CL Manzel LJ Lehman EE: Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med. 2005;172(1):85-91. 15805181 10.1164/rccm.200412-1687OC 2718449
54. Sze MA Dimitriu PA Suzuki M: Host Response to the Lung Microbiome in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;192(4):438-45. 25945594 10.1164/rccm.201502-0223OC 4595667
55. Rennard SI Fogarty C Kelsen S: The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926-34. 17290043 10.1164/rccm.200607-995OC
56. Singh S Amin AV Loke YK: Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169(3):219-29. 19204211 10.1001/archinternmed.2008.550
57. Suissa S Patenaude V Lapi F: Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029-36. 24130228 10.1136/thoraxjnl-2012-202872 3812880
58. DiSantostefano RL Li H Hinds D: Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis. Int J Chron Obstruct Pulmon Dis. 2014;9(1):457-68. 24855350 10.2147/COPD.S60498 4019612
59. Finney L Berry M Singanayagam A: Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir Med. 2014;2(11):919-32. 25240963 10.1016/S2213-2600(14)70169-9
60. Kew KM Seniukovich A: Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014; (3):CD010115. 24615270 10.1002/14651858.CD010115.pub2
61. Brightling CE Bleecker ER Panettieri RA Jr: Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2(11):891-901. 25208464 10.1016/S2213-2600(14)70187-0
62. Chiang N Dalli J Colas RA: Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J Exp Med. 2015;212(8):1203-17. 26195725 10.1084/jem.20150225 4516788
63. Bozinovski S Anthony D Anderson GP: Treating neutrophilic inflammation in COPD by targeting ALX/FPR2 resolution pathways. Pharmacol Ther. 2013;140(3):280-9. 23880288 10.1016/j.pharmthera.2013.07.007
64. Bozinovski S Uddin M Vlahos R: Serum amyloid A opposes lipoxin A 4 to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci USA. 2012;109(3):935-40. 22215599 10.1073/pnas.1109382109 3271884
65. Xue J Schmidt SV Sander J: Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014;40(2):274-88. 24530056 10.1016/j.immuni.2014.01.006 3991396
66. Hodge S Hodge G Ahern J: Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2007;37(6):748-55. 17630319 10.1165/rcmb.2007-0025OC
67. Bozinovski S Jones JE Vlahos R: Granulocyte/macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B and AP-1 in vivo. J Biol Chem. 2002;277(45):42808-14. 12208854 10.1074/jbc.M207840200
68. Lawrence T Natoli G: Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011;11(11):750-61. 22025054 10.1038/nri3088
69. Gautier EL Shay T Miller J: Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol. 2012;13(11):1118-28. 23023392 10.1038/ni.2419 3558276
70. Lenzo JC Turner AL Cook AD: Control of macrophage lineage populations by CSF-1 receptor and GM-CSF in homeostasis and inflammation. Immunol Cell Biol. 2012;90(4):429-40. 21727904 10.1038/icb.2011.58
71. Anthony D McQualter JL Bishara M: SAA drives proinflammatory heterotypic macrophage differentiation in the lung via CSF-1R-dependent signaling. FASEB J. 2014;28(9):3867-77. 24846388 10.1096/fj.14-250332
72. Gunawardana N Finney L Johnston SL: Experimental rhinovirus infection in COPD: implications for antiviral therapies. Antiviral Res. 2014;102:95-105. 24370732 10.1016/j.antiviral.2013.12.006
73. Egerman MA Glass DJ: Signaling pathways controlling skeletal muscle mass. Crit Rev Biochem Mol Biol. 2014;49(1):59-68. 24237131 10.3109/10409238.2013.857291 3913083
74. Kon SS Jones SE Schofield SJ: Gait speed and readmission following hospitalisation for acute exacerbations of COPD: a prospective study. Thorax. 2015;70(12):1131-7. 26283709 10.1136/thoraxjnl-2015-207046
75. Sharif R Parekh TM Pierson KS: Predictors of early readmission among patients 40 to 64 years of age hospitalized for chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(5):685-94. 24784958 10.1513/AnnalsATS.201310-358OC 4225809
76. Oliveira CC Lee AL McGinley J: Falls by individuals with chronic obstructive pulmonary disease: a preliminary 12-month prospective cohort study. Respirology. 2015;20(7):1096-101. 26206432 10.1111/resp.12600
77. Lach-Trifilieff E Minetti GC Sheppard K: An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014;34(4):606-18. 24298022 10.1128/MCB.01307-13 3911487
78. Bateman ED Reddel HK van Zyl-Smit RN: The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med. 2015;3(9):719-28. 26255108 10.1016/S2213-2600(15)00254-4
79. Vanfleteren LE Kocks JW Stone IS: Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax. 2014;69(1):72-9. 23794191 10.1136/thoraxjnl-2013-203602
80. Barrecheguren M Esquinas C Miravitlles M: The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med. 2015;21(1):74-9. 25405671 10.1097/MCP.0000000000000118
81. D'Urzo A Donohue JF Kardos P: A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015;16(12):1845-60. 26194213 10.1517/14656566.2015.1067682 4673525
82. Soler X Ramsdell JW: Are Asthma and COPD a Continuum of the Same Disease? J Allergy Clin Immunol Pract. 2015;3(4):489-95; quiz 496-7. 26164572 10.1016/j.jaip.2015.05.030
83. Ghebre MA Bafadhel M Desai D: Biological clustering supports both "Dutch" and "British" hypotheses of asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2015;135(1):63-72. 25129678 10.1016/j.jaci.2014.06.035 4282726
84. de Marco R Marcon A Rossi A: Asthma, COPD and overlap syndrome: a longitudinal study in young European adults. Eur Respir J. 2015;46(3):671-9. 26113674 10.1183/09031936.00008615
85. Gelb AF Yamamoto A Verbeken EK: Unraveling the Pathophysiology of the Asthma-COPD Overlap Syndrome: Unsuspected Mild Centrilobular Emphysema Is Responsible for Loss of Lung Elastic Recoil in Never Smokers With Asthma With Persistent Expiratory Airflow Limitation. Chest. 2015;148(2):313-20. 25950858 10.1378/chest.14-2483
86. Smolonska J Koppelman GH Wijmenga C: Common genes underlying asthma and COPD? Genome-wide analysis on the Dutch hypothesis. Eur Respir J. 2014;44(4):860-72. 24993907 10.1183/09031936.00001914 4217133
87. Beghé B Hall IP Parker SG: Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease. Allergy. 2010;65(4):474-81. 19796199 10.1111/j.1398-9995.2009.02167.x
88. Christenson SA Steiling K van den Berge M: Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(7):758-66. 25611785 10.1164/rccm.201408-1458OC 4407484
89. van den Berge M Steiling K Timens W: Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity. Thorax. 2014;69(1):14-23. 23925644 10.1136/thoraxjnl-2012-202878 3888587
90. Hardin M Cho M McDonald ML: The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J. 2014;44(2):341-50. 24876173 10.1183/09031936.00216013 4154588
91. Kearley J Silver JS Sanden C: Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity. 2015;42(3):566-79. 25786179 10.1016/j.immuni.2015.02.011